Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Navigen Inc (AKA: Navigen Pharmaceuticals, Inc)
Profile last edited on: 5/17/2018      CAGE: 4PV66      UEI: S8PXYJQM74M6

Business Identifier: Pharmaceutical and medical device company focused on advancing the most promising early-stage technologies into products
Year Founded
2006
First Award
2008
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

383 Colorow Drive
Salt Lake City, UT 84108
   (801) 587-1417
   info@nvgn.com
   www.navigenpharma.com
Location: Single
Congr. District: 01
County: Salt Lake

Public Profile

Navigen is a pharmaceutical and medical device company focused on advancing the most promising early-stage technologies into products. Navigen's strategy is to partner with innovative and dedicated inventors to develop their technologies. Navigen has interests in new pharmaceutical and device technologies. The company does not target any specific size or stage of project.

Extent of SBIR involvement

User Avatar
Phase I Awards
18
Phase II Awards
11
Conversion Rate
61.11%
Phase I Dollars
$4,352,707
Phase II Dollars
$22,056,900
Total Awarded
$26,409,607

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 2 NIH $9,299,392
Project Title: Therapeutic D-Peptide Inhibitor of HIV Entry
2019 1 NIH $268,075
Project Title: Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza
2019 2 NIH $323,066
Project Title: Oral/Topical D-Peptide TNF Inhibitors for Inflammatory Bowel Disease
2018 2 NIH $1,931,372
Project Title: Treating Acute Lung Injury Via Cytokine Signaling Blockade
2018 2 NIH $3,584,327
Project Title: Protease-Resistant D-Peptide Inhibitors of RSV Entry

Key People / Management

  Hunter Jackson -- Chairman and CEO

  Dean Li -- Chief Scientific Officer

  Alan L Mueller -- Vice President of Research

  Sutip Navankasattusas

  Kirill Ostanin

  Brandi Simpson -- Chief Business Officer

  Elizabeth Wang

  Brett D Welch

  Daniel A Wettstein

Company News

There are no news available.